GMPR2

Summary

GMPR2 (guanosine monophosphate reductase 2, HGNC:4377) is a protein-coding gene on chromosome 14q12, encoding GMP reductase 2 (Q9P2T1). Catalyzes the irreversible NADPH-dependent deamination of GMP to IMP.

This gene encodes an enzyme that catalyzes the irreversible and NADPH-dependent reductive deamination of guanosine monophosphate (GMP) to inosine monophosphate (IMP). The protein also functions in the re-utilization of free intracellular bases and purine nucleosides. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 51292 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 81 total
• Druggable target: yes
• MANE Select transcript: NM_001002002

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4377
Approved symbol	GMPR2
Name	guanosine monophosphate reductase 2
Location	14q12
Locus type	gene with protein product
Status	Approved
Aliases	hGMPR-II
Ensembl gene	ENSG00000100938
Ensembl biotype	protein_coding
OMIM	610781
Entrez	51292

Gene structure

Transcript identifiers

Ensembl transcripts: 56 — 46 protein_coding, 5 nonsense_mediated_decay, 3 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000355299, ENST00000399440, ENST00000420554, ENST00000456667, ENST00000557854, ENST00000558007, ENST00000558279, ENST00000558483, ENST00000558701, ENST00000558748, ENST00000558760, ENST00000558788, ENST00000558865, ENST00000558932, ENST00000559102, ENST00000559104, ENST00000559287, ENST00000559409, ENST00000559479, ENST00000559606, ENST00000559801, ENST00000559836, ENST00000559910, ENST00000559943, ENST00000560139, ENST00000560517, ENST00000561035, ENST00000561038, ENST00000561130, ENST00000895698, ENST00000895699, ENST00000895700, ENST00000895701, ENST00000895702, ENST00000895703, ENST00000895704, ENST00000895705, ENST00000895706, ENST00000895707, ENST00000895708, ENST00000895709, ENST00000920750, ENST00000920751, ENST00000920752, ENST00000920753, ENST00000920754, ENST00000920755, ENST00000920756, ENST00000920757, ENST00000920758, ENST00000920759, ENST00000920760, ENST00000920761, ENST00000959776, ENST00000959777, ENST00000959778

RefSeq mRNA: 12 — MANE Select: NM_001002002 NM_001002000, NM_001002001, NM_001002002, NM_001283021, NM_001283022, NM_001283023, NM_001351022, NM_001351023, NM_001351024, NM_001351025, NM_001351026, NM_016576

CCDS: CCDS41935, CCDS45087, CCDS61419, CCDS73624

Canonical transcript exons

ENST00000399440 — 10 exons

Exon	Start	End
ENSE00002548393	24238589	24239242
ENSE00002568743	24232929	24232977
ENSE00003459451	24233479	24233598
ENSE00003521369	24233219	24233340
ENSE00003557131	24237245	24237351
ENSE00003592041	24238246	24238405
ENSE00003615921	24235737	24235820
ENSE00003656574	24237071	24237152
ENSE00003666478	24237520	24237562
ENSE00003786004	24235967	24236140

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 98.01.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 32.4871 / max 286.2854, expressed in 1815 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
139016	12.7368	1771
139012	10.0391	1763
139015	4.1530	1547
139011	3.7874	1593
139013	1.4206	1035
139014	0.3502	178

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right adrenal gland	UBERON:0001233	98.01	gold quality
right adrenal gland cortex	UBERON:0035827	97.90	gold quality
left adrenal gland	UBERON:0001234	97.87	gold quality
left adrenal gland cortex	UBERON:0035825	97.81	gold quality
adrenal gland	UBERON:0002369	97.60	gold quality
gall bladder	UBERON:0002110	97.16	gold quality
thyroid gland	UBERON:0002046	97.06	gold quality
metanephros cortex	UBERON:0010533	97.04	gold quality
left lobe of thyroid gland	UBERON:0001120	97.01	gold quality
right uterine tube	UBERON:0001302	97.01	gold quality
right lobe of thyroid gland	UBERON:0001119	96.96	gold quality
adult mammalian kidney	UBERON:0000082	96.90	gold quality
lymph node	UBERON:0000029	96.87	gold quality
fallopian tube	UBERON:0003889	96.73	gold quality
blood	UBERON:0000178	96.69	gold quality
descending thoracic aorta	UBERON:0002345	96.68	gold quality
monocyte	CL:0000576	96.52	gold quality
spleen	UBERON:0002106	96.52	gold quality
leukocyte	CL:0000738	96.50	gold quality
cortex of kidney	UBERON:0001225	96.47	gold quality
pituitary gland	UBERON:0000007	96.45	gold quality
mucosa of stomach	UBERON:0001199	96.42	gold quality
stromal cell of endometrium	CL:0002255	96.41	gold quality
granulocyte	CL:0000094	96.35	gold quality
adenohypophysis	UBERON:0002196	96.31	gold quality
kidney	UBERON:0002113	96.29	gold quality
left ovary	UBERON:0002119	96.29	gold quality
popliteal artery	UBERON:0002250	96.29	gold quality
tibial artery	UBERON:0007610	96.29	gold quality
calcaneal tendon	UBERON:0003701	96.28	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.91
E-MTAB-7249	no	157.57
E-MTAB-6911	no	143.68
E-MTAB-10290	no	58.06

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

31 targeting GMPR2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-202-3P	99.84	71.41	1290
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-5093	99.67	69.26	2291
HSA-MIR-516A-3P	99.46	67.96	1378
HSA-MIR-516B-3P	99.46	67.96	1378
HSA-MIR-7162-5P	99.46	68.08	1368
HSA-MIR-4797-5P	99.39	68.01	1354
HSA-MIR-3606-5P	99.31	69.67	1168
HSA-MIR-1909-5P	98.94	64.01	484
HSA-MIR-2355-5P	98.83	65.51	1589
HSA-MIR-4451	98.82	68.17	1455
HSA-MIR-3922-5P	98.77	66.53	1059
HSA-MIR-5585-5P	97.95	68.80	1024
HSA-MIR-493-3P	97.50	66.44	731
HSA-MIR-6791-3P	97.45	64.31	1123

Literature-anchored findings (GeneRIF, showing 4)

• Data suggest the existence of two distinct types of human GMP reductase molecular species, which can be used to explain the bimodal saturation curve noted with purified human erythrocyte GMP reductase. (PMID:12009299)
• GMPR2 is a novel human GMP reductase, and overexpression of GMPR2 can promote the monocytic differentiation of HL-60 leukemia cells. (PMID:12669231)
• A single crystal structure of human GMPR type 2 with IMP and NADPH fortuitously captures three different states, each of which mimics a distinct step in the catalytic cycle of guanosine monophosphate reductase(GMPR). (PMID:22037469)
• Loss of expression of GMPR2 and PPARalpha is associated with breast cancer basal phenotype; indicating that they may play a role in carcinogenesis. (PMID:23208589)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	gmpr2	ENSDARG00000061301
mus_musculus	Gmpr2	ENSMUSG00000002326
rattus_norvegicus	Gmpr2	ENSRNOG00000020216
caenorhabditis_elegans		WBGENE00020682

Paralogs (3): IMPDH1 (ENSG00000106348), GMPR (ENSG00000137198), IMPDH2 (ENSG00000178035)

Protein

Protein identifiers

GMP reductase 2 — Q9P2T1 (reviewed: Q9P2T1)

Alternative names: Guanosine 5’-monophosphate oxidoreductase 2

All UniProt accessions (20): Q9P2T1, A0A0B4J281, H0YK13, H0YK71, H0YKE1, H0YKK3, H0YL68, H0YLB8, H0YLV5, H0YMB3, H0YMG3, H0YMR9, H0YMV5, H0YMW6, H0YN22, H0YN74, H0YNH0, H0YNJ6, H0YNS9, Q6PKC0

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the irreversible NADPH-dependent deamination of GMP to IMP. It functions in the conversion of nucleobase, nucleoside and nucleotide derivatives of G to A nucleotides, and in maintaining the intracellular balance of A and G nucleotides. Plays a role in modulating cellular differentiation.

Subunit / interactions. Homotetramer.

Tissue specificity. Highly expressed in heart, skeletal muscle, kidney, brain, liver, prostate, spleen, placenta, testis and ovary. Low expression in colon, thymus and peripheral blood leukocytes.

Similarity. Belongs to the IMPDH/GMPR family. GuaC type 1 subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9P2T1-1	1	yes
Q9P2T1-2	2
Q9P2T1-3	3

RefSeq proteins (12): NP_001002000, NP_001002001, NP_001002002, NP_001269950, NP_001269951, NP_001269952, NP_001337951, NP_001337952, NP_001337953, NP_001337954, NP_001337955, NP_057660 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001093	IMP_DH_GMPRt	Domain
IPR005993	GMPR	Family
IPR013785	Aldolase_TIM	Homologous_superfamily
IPR015875	IMP_DH/GMP_Rdtase_CS	Conserved_site
IPR050139	GMP_reductase	Family

Pfam: PF00478

Enzyme classification (BRENDA):

• EC 1.7.1.7 — GMP reductase (BRENDA: 18 organisms, 39 substrates, 64 inhibitors, 37 Km, 4 kcat entries)

Substrate kinetics (BRENDA)

7 substrates with measured Km, best-characterized 7. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
GMP	0.0014–0.38	15
NADPH	0.0085–0.12	12
NADP+	0.05–0.42	3
IMP	0.023–1.1	2
DGMP	0.015	1
DIMP	0.14	1
GUANOSINE 5’-PHOSPHATE	0.0055	1

Catalyzed reactions (Rhea), 1 shown:

• IMP + NH4(+) + NADP(+) = GMP + NADPH + 2 H(+) (RHEA:17185)

UniProt features (67 total): strand 20, binding site 15, helix 15, turn 4, mutagenesis site 3, sequence conflict 3, active site 2, splice variant 2, chain 1, modified residue 1, sequence variant 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
2C6Q	X-RAY DIFFRACTION	1.7
2BZN	X-RAY DIFFRACTION	2.15
2A7R	X-RAY DIFFRACTION	3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9P2T1-F1	96.88	0.94

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 186 (thioimidate intermediate); 188 (proton donor/acceptor)

Ligand- & substrate-binding residues (15): 189; 219–221; 242–243; 268–270; 269 (in other chain); 285–286 (in other chain); 286–290; 314–317; 26–27; 78 (in other chain); 129–131 (in other chain); 180–181 (in other chain) …

Post-translational modifications (1): 291

Mutagenesis-validated functional residues (3):

Position	Phenotype
186	loss of enzyme activity.
188	loss of enzyme activity.
289	loss of enzyme activity.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-74217	Purine salvage

MSigDB gene sets: 128 (showing top): GSE45365_NK_CELL_VS_CD8_TCELL_DN, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, CMYB_01, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, chr14q12, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, GOBP_NUCLEOBASE_METABOLIC_PROCESS, WTGAAAT_UNKNOWN, CYTAGCAAY_UNKNOWN, KEGG_PURINE_METABOLISM, GOBP_PURINE_NUCLEOBASE_METABOLIC_PROCESS, MYB_Q3, RYTTCCTG_ETS2_B, ELK1_01

GO Biological Process (5): purine nucleobase metabolic process (GO:0006144), GMP metabolic process (GO:0046037), purine nucleotide metabolic process (GO:0006163), purine nucleotide biosynthetic process (GO:0006164), nucleotide metabolic process (GO:0009117)

GO Molecular Function (6): GMP reductase activity (GO:0003920), metal ion binding (GO:0046872), catalytic activity (GO:0003824), IMP dehydrogenase activity (GO:0003938), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)

GO Cellular Component (2): cytosol (GO:0005829), GMP reductase complex (GO:1902560)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Nucleotide salvage	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
purine-containing compound metabolic process	2
nucleobase metabolic process	1
purine ribonucleotide metabolic process	1
purine ribonucleoside monophosphate metabolic process	1
nucleotide metabolic process	1
purine nucleotide metabolic process	1
nucleotide biosynthetic process	1
purine-containing compound biosynthetic process	1
nucleoside phosphate metabolic process	1
oxidoreductase activity, acting on other nitrogenous compounds as donors, with NAD or NADP as acceptor	1
cation binding	1
molecular_function	1
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	1
binding	1
catalytic activity	1
cytoplasm	1
cellular anatomical structure	1
oxidoreductase complex	1

Protein interactions and networks

STRING

2028 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GMPR2	UMPS	P11172	376
GMPR2	PCYT2	Q99447	361
GMPR2	ALDH18A1	P54886	353
GMPR2	GART	P22102	353
GMPR2	GDA	Q9Y2T3	351
GMPR2	H6PD	O95479	350
GMPR2	ORMDL2	Q53FV1	347
GMPR2	DHODH	Q02127	340
GMPR2	HNRNPH3	P31942	337
GMPR2	ACP1	P24666	329
GMPR2	YARS1	P54577	327
GMPR2	YARS2	Q9Y2Z4	310
GMPR2	SARNP	P82979	299
GMPR2	PFAS	O15067	297
GMPR2	PIP4K2C	Q8TBX8	282

IntAct

12 interactions, top by confidence:

A	B	Type	Score
MEOX2	GMPR2	psi-mi:“MI:0915”(physical association)	0.560
ERBB2	GMPR2	psi-mi:“MI:0915”(physical association)	0.550
GMPR2	GMPR	psi-mi:“MI:0914”(association)	0.500
GMPR	GMPR2	psi-mi:“MI:0915”(physical association)	0.500
	GMPR2	psi-mi:“MI:0407”(direct interaction)	0.440
lepB	GMPR2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (35): GMPR2 (Two-hybrid), GMPR (Affinity Capture-MS), SNX17 (Affinity Capture-MS), GMPR2 (Two-hybrid), SNX17 (Affinity Capture-MS), GMPR (Affinity Capture-MS), GMPR2 (Affinity Capture-MS), GMPR2 (Two-hybrid), GMPR2 (Affinity Capture-MS), GMPR2 (Affinity Capture-MS), GMPR2 (Positive Genetic), SNX17 (Affinity Capture-MS), GMPR (Affinity Capture-MS), GMPR2 (Affinity Capture-MS), GMPR2 (Co-fractionation)

ESM2 similar proteins: A3KN12, O88958, P21265, P21343, P30566, P36959, P38024, P50554, P50990, P54822, P61922, P78371, P80147, P80314, P80404, P82197, Q04447, Q0II59, Q259G4, Q2KIG0, Q3ZBF0, Q3ZBH0, Q3ZCI9, Q41141, Q4R4U1, Q4R5J0, Q4R5Y2, Q4R6F8, Q5E982, Q5R5F8, Q5RAP1, Q5XIM9, Q5ZMA6, Q64422, Q6EE31, Q6IA69, Q711T7, Q7XPW5, Q7ZV22, Q812E8

Diamond homologs: A0A0B5L585, A0JNA3, A8HAF6, A9A5Y7, B0TQE1, B0UXP9, B1L5U5, B5EUG3, D3ZLZ7, E9BDA8, E9PU28, F1DBB2, F6S675, F7CYY5, O00086, O14344, O42831, O50316, O58045, O67820, P0ADG7, P0ADG8, P0ADG9, P0C0H6, P0C0H7, P0DB88, P0DB89, P12268, P12269, P20839, P21620, P21879, P24547, P31002, P36959, P38697, P39567, P42851, P44334, P47996

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

81 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	61
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1605 predictions. Top by Δscore:

Variant	Effect	Δscore
14:24233594:GTAAG:G	donor_loss	1.0000
14:24233595:TAAG:T	donor_loss	1.0000
14:24233596:AAG:A	donor_loss	1.0000
14:24233598:GGTAG:G	donor_loss	1.0000
14:24233599:GTA:G	donor_loss	1.0000
14:24233600:T:A	donor_loss	1.0000
14:24235735:A:AG	acceptor_gain	1.0000
14:24235736:G:GG	acceptor_gain	1.0000
14:24235736:GTTCT:G	acceptor_gain	1.0000
14:24235963:ACAG:A	acceptor_loss	1.0000
14:24235964:CA:C	acceptor_loss	1.0000
14:24235965:A:AG	acceptor_gain	1.0000
14:24235966:G:GA	acceptor_gain	1.0000
14:24235966:GC:G	acceptor_gain	1.0000
14:24235966:GCA:G	acceptor_gain	1.0000
14:24235966:GCAT:G	acceptor_gain	1.0000
14:24235966:GCATC:G	acceptor_gain	1.0000
14:24236141:G:GG	donor_gain	1.0000
14:24236142:T:G	donor_loss	1.0000
14:24237240:CCTA:C	acceptor_loss	1.0000
14:24237241:CTAG:C	acceptor_loss	1.0000
14:24237242:TA:T	acceptor_loss	1.0000
14:24237243:A:AG	acceptor_gain	1.0000
14:24237243:AGG:A	acceptor_loss	1.0000
14:24237244:G:GA	acceptor_gain	1.0000
14:24237244:G:GT	acceptor_loss	1.0000
14:24237244:GGCT:G	acceptor_gain	1.0000
14:24237347:TTTCA:T	donor_gain	1.0000
14:24237348:TTCA:T	donor_gain	1.0000
14:24237349:TCAG:T	donor_loss	1.0000

AlphaMissense

2288 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:24233297:T:A	V15D	1.000
14:24233300:T:C	L16P	1.000
14:24233309:C:A	P19H	1.000
14:24237147:G:A	G181E	1.000
14:24233308:C:T	P19S	0.999
14:24233309:C:G	P19R	0.999
14:24233317:A:C	S22R	0.999
14:24233319:T:A	S22R	0.999
14:24233319:T:G	S22R	0.999
14:24233553:T:A	N54K	0.999
14:24233553:T:G	N54K	0.999
14:24235979:A:C	S102R	0.999
14:24235981:C:A	S102R	0.999
14:24235981:C:G	S102R	0.999
14:24237074:G:T	G157W	0.999
14:24237079:T:A	N158K	0.999
14:24237079:T:G	N158K	0.999
14:24237108:T:C	L168P	0.999
14:24237136:A:C	K177N	0.999
14:24237136:A:T	K177N	0.999
14:24237146:G:A	G181R	0.999
14:24237146:G:C	G181R	0.999
14:24237146:G:T	G181W	0.999
14:24237245:G:A	G183D	0.999
14:24237253:T:C	C186R	0.999
14:24237254:G:A	C186Y	0.999
14:24237255:T:G	C186W	0.999
14:24237275:G:A	G193E	0.999
14:24237280:G:A	G195R	0.999
14:24237280:G:C	G195R	0.999

dbSNP variants (sampled 300 via entrez): RS1000034305 (14:24231642 G>A), RS1000316790 (14:24231721 A>G), RS1000504150 (14:24239597 T>A), RS1000668709 (14:24231432 CA>C,CAA), RS1000777262 (14:24236526 G>A), RS1001953122 (14:24233434 T>C,G), RS1002011023 (14:24235404 A>G,T), RS1002190626 (14:24237587 G>A), RS1002787536 (14:24233095 G>A,C), RS1002797157 (14:24233399 A>G), RS1003240383 (14:24239265 A>G), RS1003416799 (14:24235105 A>G), RS1003494371 (14:24236834 G>A), RS1004141790 (14:24234201 T>C,G), RS1004478968 (14:24232762 C>A,G)

Disease associations

OMIM: gene MIM:610781 | disease phenotypes: MIM:127550

GenCC curated gene-disease

Mondo (1): dyskeratosis congenita (MONDO:0015780)

Orphanet (1): Dyskeratosis congenita (Orphanet:1775)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST010002_197	Refractive error	5.000000e-10
GCST90002390_259	Mean corpuscular hemoglobin	3.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004527	mean corpuscular hemoglobin

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D019871	Dyskeratosis Congenita	C15.378.190.223.500.750; C16.131.831.150; C16.320.322.108; C16.320.850.235; C17.800.804.150; C17.800.827.235

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4296017 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects cotreatment, increases abundance, increases expression, affects expression, decreases expression	4
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	2
Acrolein	affects cotreatment, increases oxidation, increases abundance	2
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, decreases expression	2
Ozone	affects cotreatment, increases oxidation, increases abundance	2
Particulate Matter	increases abundance, decreases expression	2
FR900359	increases phosphorylation	1
ginger extract	affects cotreatment, affects expression, increases abundance	1
dicrotophos	decreases expression	1
2,4,6-tribromophenol	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
tetrabromobisphenol A	decreases expression	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
deguelin	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
(+)-JQ1 compound	decreases expression	1
bisphenol AF	increases expression	1
Acetaminophen	decreases expression	1
Vehicle Emissions	decreases expression, increases abundance	1
Carbamazepine	affects expression	1
Cisplatin	increases expression	1
Dexamethasone	increases expression, affects cotreatment	1
Doxorubicin	decreases expression	1
Indomethacin	affects cotreatment, increases expression	1
Ivermectin	decreases expression	1
Oils, Volatile	affects cotreatment, affects expression, increases abundance	1
Rotenone	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4189877	Binding	Inhibition of human GMPR2 using GMP as substrate by spectrophotometric method	Expanding Benzoxazole-Based Inosine 5’-Monophosphate Dehydrogenase (IMPDH) Inhibitor Structure-Activity As Potential Antituberculosis Agents. — J Med Chem

Clinical trials (associated diseases)

18 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00004787	PHASE2	COMPLETED	Phase II Pilot Study of Granulocyte Colony-Stimulating Factor for Inherited Bone Marrow Failure Syndromes
NCT01659606	PHASE2	ACTIVE_NOT_RECRUITING	Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
NCT03579875	PHASE2	RECRUITING	Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
NCT04232085	PHASE2	RECRUITING	Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures
NCT04638517	PHASE2	TERMINATED	The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis
NCT01917708	PHASE1	COMPLETED	Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
NCT06477614	PHASE1	RECRUITING	Anti-cancer DC Cell Vaccination to Treat Solid Tumors
NCT06817590	PHASE1	RECRUITING	Nucleoside Therapy in Patients With Telomere Biology Disorders
NCT00455312	PHASE2/PHASE3	COMPLETED	Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA
NCT01001598	PHASE1/PHASE2	TERMINATED	Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita
NCT00027274	Not specified	RECRUITING	Cancer in Inherited Bone Marrow Failure Syndromes
NCT00499070	Not specified	COMPLETED	Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment
NCT01319851	Not specified	TERMINATED	Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
NCT02162420	Not specified	COMPLETED	Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
NCT02720679	Not specified	RECRUITING	Investigation of the Genetics of Hematologic Diseases
NCT03050268	Not specified	RECRUITING	Familial Investigations of Childhood Cancer Predisposition
NCT04959188	Not specified	COMPLETED	Needs Assessment for Individuals and Families Affected by Dyskeratosis Congenita (DC) and Related Telomere Biology Disorders (TBD)
NCT06731036	Not specified	AVAILABLE	Expanded Access to CD34+ Selection Utilizing Miltenyi CliniMACS Prodigy® for Patients Receiving Peripheral Blood Stem Cell Transplantations and Stem Cell Boosts